Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for inclisiran (Leqvio®) as an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) level in adults with heterozygous familial hypercholesterolemia (HeFH) who are on the maximally tolerated dose of a statin, with or without other LDL-C -lowering therapies.